Just In: Boston Scientific Acquires Nalu Medical for $533 Million
The acquisition brings a novel neurostimulation device into Boston Scientific’s portfolio, expanding its capacity to pro...
The global drugmaker calls on startups to help tackle critical challenges in drug development, manufacturing, and patient care.
The acquisition brings a novel neurostimulation device into Boston Scientific’s portfolio, expanding its capacity to pro...
AstraZeneca’s Bax24 Phase III trial demonstrates sustained blood pressure control and a favorable safety profile in pati...
Industry analysts warn the move could signal broader consolidation and narrower choices for members in rural areas.
Cost-cutting move reflects margin squeeze and rising competition in the weight-loss drug market.
Lilly’s Zepbound shows superior results in weight loss, offering a potential edge in the $150 billion obesity drug market.
“We will invest in exceptional talent to scale up our customer outreach and to support passionate clinicians who want to...